默沙东第一季度财报解读:收入同比下滑,核心驱动与短期挑战并存

药事纵横
25 Apr

4月24日,默沙东公布了2025年第一季度财务业绩。报告显示,公司全球销售额达155亿美元,同比下降2%(剔除汇率影响后增长1%),非GAAP每股收益(EPS)为2.22美元,同比增长7%。尽管面临汇率波动和部分产品需求波动的挑战,核心产品KEYTRUDA和动物健康业务表现亮眼,研发管线亦取得多项里程碑进展。财务表现:核心驱动与短期挑战并存收入概况2025年第一季度,默沙东全球销售额为155.29...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10